en · de · es
ipamorelin-notes.peptides1126.com › Info › Ipamorelin Background And Mechanism — Evidence Review

Ipamorelin Background And Mechanism — Evidence Review

By Editorial Desk · published 2025-10-02 · last reviewed 2025-11-20 · Info

If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-11-20. Where a claim depends on a specific study, the study is described rather than over-claimed.

Ipamorelin Background and Mechanism

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.

Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.

Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.

背景与分子特征

Ipamorelin 是一种合成五肽,序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2,分子式 C38H49N9O5,游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素(GHS)家族,作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道,设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。

在 GHS 家族中,早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放,并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性,对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同,而完整的分子解释仍有待补充。需要区分的是,选择性是研究观察中的相对程度,并非绝对界限。

从用途定位看,ipamorelin 目前主要以研究用肽的身份被讨论,未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用,不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小,因此对其效应强度与一致性的描述应保持谨慎。

Ipamorelin at a glance

PropertyValueNotes
Molecular formulaC38H49N9O5Includes two non-natural residues
Molecular weightAbout 711.9 g/molConfirmed by mass spectrometry
AppearanceWhite to off-white powderTypical lyophilized form
Receptor targetGHS-R1aGhrelin receptor agonist
Plasma half-lifeRoughly 2 hoursVaries by species and assay

Receptor Mechanism and Secretagogue Action

Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.

At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.

Related pages on this site

Background and Structural Identity

The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.

Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.

Reference notes

=== Physical === Cardiovascular side effects can include hypertension or hypotension from a vasovagal response, Raynaud's phenomenon (reduced blood flow to the hands and feet), and tachycardia (increased heart rate). Sexual side effects in males may include erectile dysfunction, frequent erections, or prolonged erections. Gastrointestinal side effects may include abdominal pain, constipation, diarrhea, and nausea. Other potential physical side effects include appetite loss, blurred vision, dry mouth, excessive grinding of the teeth, nosebleed, profuse sweating, rhinitis medicamentosa (drug-induced nasal congestion), reduced seizure threshold, tics (a type of movement disorder), and weight loss. Dangerous physical side effects are rare at typical pharmaceutical doses. Amphetamine stimulates the medullary respiratory centers, producing faster and deeper breaths. In a normal person at therapeutic doses, this effect is usually not noticeable, but when respiration is already compromised, it may be evident. Amphetamine also induces contraction in the urinary bladder sphincter, the muscle which controls urination, which can result in difficulty urinating. This effect can be useful in treating bed wetting and loss of bladder control. The effects of amphetamine on the gastrointestinal tract are unpredictable. If intestinal activity is high, amphetamine may reduce gastrointestinal motility (the rate at which content moves through the digestive system); however, amphetamine may increase motility when the smooth muscle of the tract is relaxed.

===== Half-life ===== The half-life of delta bilirubin is equivalent to that of albumin since the former is bound to the latter, yields 2–3 weeks. A free-of-bound bilirubin has a half-life of 2 to 4 hours.

Aromatic hydrocarbons contain conjugated double bonds. This means that every carbon atom in the ring is sp2 hybridized, allowing for added stability. The most important example is benzene, the structure of which was formulated by Kekulé who first proposed the delocalization or resonance principle for explaining its structure. For "conventional" cyclic compounds, aromaticity is conferred by the presence of 4n + 2 delocalized pi electrons, where n is an integer. Particular instability (antiaromaticity) is conferred by the presence of 4n conjugated pi electrons.

Sources: en.wikipedia.org

Reference notes

== Mechanisms == Addiction develops when repeated exposure to a rewarding stimulus produces lasting changes in the brain circuits that govern reward, stress and self-control. Current accounts describe this as a recurring three-stage cycle. During binge/intoxication, dopaminergic signaling in the basal ganglia gives the drug and the cues surrounding it a powerful pull on attention and behavior. During withdrawal/negative affect, brain stress systems in the extended amygdala become overactive and ordinary pleasures become muted, so that use is increasingly driven by relief rather than reward. During preoccupation/anticipation, reduced prefrontal cortex control over these systems leaves craving poorly restrained and makes relapse more likely. Each stage is associated with persistent changes in gene expression and synaptic plasticity within the affected circuits. In laboratory animals, repeated drug exposure causes a protein called ΔFosB to accumulate in reward-related neurons, which increases drug self-administration and blunts sensitivity to adverse consequences; it is used in preclinical research as a marker of addiction.

In this method, polyvinylpyrrolidone (PVP) is dissolved in water by sonication and mixed with silver colloid particles. Active stirring ensures the PVP has adsorbed to the nanoparticle surface. Centrifuging separates the PVP coated nanoparticles which are then transferred to a solution of ethanol to be centrifuged further and placed in a solution of ammonia, ethanol and Si(OEt4) (TES). Stirring for twelve hours results in the silica shell being formed consisting of a surrounding layer of silicon oxide with an ether linkage available to add functionality. Varying the amount of TES allows for different thicknesses of shells formed. This technique is popular due to the ability to add a variety of functionality to the exposed silica surface.

Although American rocket pioneer Robert H. Goddard developed, patented, and flew small liquid-propellant rockets as early as 1914, the United States was the only one of the three major allied World War II powers to not have its own rocket program, until Von Braun and his engineers were expatriated from Nazi Germany in 1945. The US acquired a large number of V-2 rockets and recruited von Braun and most of his engineering team in Operation Paperclip. The team was sent to the Army's White Sands Proving Ground in New Mexico, in 1945. They set about assembling the captured V-2s and began a program of launching them and instructing American engineers in their operation. These tests led to the first photos of Earth from space, and the first two-stage rocket, the WAC Corporal-V-2 combination, in 1949. The German rocket team was moved from Fort Bliss to the Army's new Redstone Arsenal, located in Huntsville, Alabama, in 1950. From here, von Braun and his team developed the Army's first operational medium-range ballistic missile, the Redstone rocket, derivatives of which launched both America's first satellite, and the first piloted Mercury space missions. It became the basis for both the Jupiter and Saturn family of rockets.

Sources: en.wikipedia.org

Reference notes

α, catalytic domain, has two paralogous versions: α1 and α2 which are encoded from PRKAA1 and PRKAA2 β, regulatory domain, has two paralogous versions: β1 and β2 which are encoded from PRKAB1 and PRKAB2 γ, regulatory domain, has three paralogous versions: γ1, γ2, and γ3 which are encoded from PRKAG1, PRKAG2, and PRKAG3 In human skeletal muscle, the preferred form is α2β2γ1. But in the human liver, the most abundant form is α1β2γ1.

Therefore, most of the silver found in wastewater treatment plants is in the form of silver nanoparticles or silver precipitates such as Ag2S and AgCl. The amount of silver precipitate formed depends on silver ion release, which increases with increasing dissolved oxygen concentration and decreasing pH. Silver ions account for approximately 1% of total silver after silver nanoparticles are suspended in aerated water. In anoxic wastewater treatment environments, silver ion release is therefore often negligible, and most of the silver nanoparticles in wastewater remain in the original silver nanoparticle form. The presence of natural organic matter can also decrease oxidative dissolution rates and therefore the release rate of free silver ions. The slow oxidation of silver nanoparticles may enable new pathways for its transfer into the environment.

Potent and selective MMP-3 inhibitors have been developed by using a hydroxypyrone as the zinc binding group. By attaching an aryl backbone to the 2-position of the pyrone ring, more selectivity was gained. On the hydroxypyrone ring, three positions are available to attach backbones, position 2-, 5- and 6-. Hydroxypyrone-based MMP inhibitors are structurally corresponding to the pyrimidinetriones. A recent inhibitor is the compound 3-hydroxypyran-4-one nominated 868368-30-3. It is MMP-3 selective and its 0,0-bidentate chelation of zinc is the structural part proposed to be responsible for the MMP recognition.

Apryll Marie Stalcup is an American chemist who is Professor and was the Director of the Irish Separation Science Cluster at Dublin City University. She was awarded the 2021 Chromatography Forum of the Delaware Valley Stephen Dal Nogare Award, the 2015 American Microchemical Society Benedetti Pichler Award and named in the 2016 Power List of the Top 50 Women Analytical Scientists worldwide. Her research considers surface-confined ionic liquids and chiral separations.

Sources: en.wikipedia.org

Frequently asked questions

What is the amino acid sequence of ipamorelin?

The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.

How does ipamorelin differ from earlier growth hormone secretagogues?

It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.

Is ipamorelin an approved medicine?

No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.

Ipamorelin 与 GHRP-6 有什么不同?

两者都是 GHS-R1a 激动剂,但 ipamorelin 在研究中显示出更高的生长激素释放选择性。早期资料显示它对皮质醇、催乳素与食欲的刺激弱于 GHRP-6。这些差异是相对程度,而非绝对区分。

Network